Bone Biologics Corporation reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 8.95 million compared to USD 1.48 million a year ago. Basic loss per share from continuing operations was USD 34.01 compared to USD 31.15 a year ago.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.655 USD | -0.29% | +4.10% | -63.38% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-63.38% | 1.46M | |
+13.20% | 130B | |
-8.56% | 10.99B | |
-4.33% | 8.35B | |
+41.89% | 5.67B | |
-23.62% | 4.72B | |
+7.67% | 3.42B | |
-10.53% | 2.76B | |
-13.58% | 1.92B | |
-27.77% | 1.68B |
- Stock Market
- Equities
- BBLG Stock
- News Bone Biologics Corporation
- Bone Biologics Corporation Reports Earnings Results for the Full Year Ended December 31, 2023